retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [3] | INCMGA0012 | MGA012
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a clinical stage humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interation between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint inhibitor.
Click here for help
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
International Nonproprietary Names Click here for help
INN number INN
11095 retifanlimab
Synonyms Click here for help
hPD-1 mAb 7(1.2) [3] | INCMGA0012 | MGA012
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 968
Other databases
GtoPdb PubChem SID 442878617
Search PubMed clinical trials retifanlimab
Search PubMed titles retifanlimab
Search PubMed titles/abstracts retifanlimab